Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma

• Main Authors: Chai, Chee Shee, Liam, Chong Kin, Lin, O. Po, Pang, Yong Kek, Ho, G. F., Alip, A., Wong, C. K., Poh, M. E.
• Format: E-Article
• Language: English
• Published: Oxford University Press 2019
• Subjects: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://ir.unimas.my/id/eprint/28061/1/ESMO%20Asia%202019%201.pdf; http://ir.unimas.my/id/eprint/28061/; https://doi.org/10.1093/annonc/mdz437.013
• Institution: Universiti Malaysia Sarawak

Abstract Background Afatinib is an irreversible second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) while gefitinib or erlotinib are reversible first-generation EGFR-TKIs. Methods A retrospective analysis of patients with EGFR mutant advanced lung adenocar...